

Speaker Profile

Vance G. Fowler, Jr. MD, MHS. Dr. Fowler is Professor of Medicine with Tenure, Department of Medicine and Department of Molecular Genetics and Microbiology at Duke University. Dr. Fowler's research in *S. aureus* and antibacterial resistance has led to more than 20 years (1999-2021) of continuous NIH funding as PI. According to the Blue Ridge Institute for Medical Research, he has been in the top 30 Internal Medicine PIs for total NIH funding to US Medical Schools consistently since 2014.

He is Contact PI of the Antibacterial Resistance Leadership Group (ARLG), a grant with a total value of over \$100 million to design, prioritize, and execute clinical research in antibacterial resistance. The ARLG was specifically praised in the Obama Administration's March 2016 Presidential Advisory Council on Combatting Antibiotic-Resistant Bacteria (PACCARB). He created the *S. aureus* Bacteremia Group (SABG), one of the world's largest prospective biorepositories of SAB.

He is co-founder of the International Collaboration on Endocarditis (ICE), and published the critical observation that *S. aureus* is now the leading cause of endocarditis in the industrialized world. He was lead author on the Phase III trial that led to the FDA indication of daptomycin for SAB and on the multinational trial of Merck V710 vaccine for *S. aureus*. He was senior author on two Phase II trials of immunotherapeutic treatments of SAB and a recently completed NIH-funded trial on staphylococcal bacteremia worth \$20 million. In 2012, he received the Clinical Research Achievement Award for publishing one of the top ten clinical research papers in the US.